Results 61 to 70 of about 20,096 (124)

Matrix metalloproteinase‐9 regulates cell adhesion and membrane protrusive activity of ovarian cancer cells

FEBS Open Bio, Volume 16, Issue 7, Page 1414-1427, July 2026.
Matrix metalloproteinase‐9 (MMP9) drives ovarian cancer progression. Using MMP9‐null cells (M9‐KO) created from ovarian cancer cells, we found MMP9 loss did not block Epidermal Growth Factor (EGF)‐driven E‐cadherin dissolution or EMT but delayed and reduced EGF‐driven membrane protrusions. Transient MMP9 re‐expression drove membrane protrusion.
Claire Strauel, Sam Bennett, Natalie Ehlinger, Nelson Cook, Katelyn Marvin, Caleb L. Lines, Sam Reyes, Brooke Kirby, Shawn M. Ellerbroek   +8 more
wiley   +1 more source

Regulation of Cell Proliferation and Migration by Extracellular Phosphatidic Acid

Biomedicines
Phosphatidic acid (PA) is increasingly recognized as an important endogenous regulator of cell proliferation and migration, playing relevant roles in physiology and pathology.
Ana Gomez-Larrauri, Asier Benito-Vicente, Kepa B. Uribe, Cesar Martin, Antonio Gomez-Muñoz   +4 more
doaj   +1 more source

The Role of PPARγ in the Transcriptional Control by Agonists and Antagonists

PPAR Research, 2012
In recent years, peroxisome proliferator-activated receptor gamma (PPARγ) has been reported to be a target for the treatment of type II diabetes. Furthermore, it has received attention for its therapeutic potential in many other human diseases, including
Tamotsu Tsukahara
doaj   +1 more source

Novel Autotaxin Inhibitor ATX-1d Significantly Enhances Potency of Paclitaxel—An In Silico and In Vitro Study

Molecules
The development of drug resistance in cancer cells poses a significant challenge for treatment, with nearly 90% of cancer-related deaths attributed to it.
Prateek Rai, Christopher J. Clark, Carl B. Womack, Curtis Dearing, Joshua Thammathong, Derek D. Norman, Gábor J. Tigyi, Subhabrata Sen, Kevin Bicker, April M. Weissmiller, Souvik Banerjee   +10 more
doaj   +1 more source

Lysophospholipid receptors in vertebrate development, physiology, and pathology

Journal of Lipid Research, 2009
Lysophospholipid (LP) research has experienced a period of renaissance with the discovery of the lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) receptors in the late 1990s.
Athanasia Skoura, Timothy Hla
doaj   +1 more source

Lysophosphatidic acid receptor 1 antagonist (EPGN2154) causes regression of NASH in preclinical NASH models. [PDF]

Hepatol Commun, 2023
Bhattacharjee J, Beaton G, Ravula SB, Lee SJ, Bacon KB, Jenkinson CP, Warren M, Tucci FC, Kohli R.   +8 more
europepmc   +1 more source

Liraglutide attenuates aluminum chloride-induced Alzheimer’s disease in rats by modulating the oxLDL/LPA/LPAR1 pathway

Communications Biology
Aluminum toxicity in rodents is well documented to be used for inducing experimental models that mimic the clinical phenotypes of Alzheimer’s disease (AD).
Nada F. Abo El-Magd, Nehal M. Ramadan, Salma M. Eraky   +2 more
doaj   +1 more source

Autotaxin-lysophosphatidic acid receptor 5 axis evokes endothelial dysfunction via reactive oxygen species signaling. [PDF]

Exp Biol Med (Maywood), 2023
Janovicz A, Majer A, Kosztelnik M, Geiszt M, Chun J, Ishii S, Tigyi GJ, Benyó Z, Ruisanchez É.   +8 more
europepmc   +1 more source

In vitro pharmacological characterization of standard and new lysophosphatidic acid receptor antagonists using dynamic mass redistribution assay. [PDF]

Front Pharmacol, 2023
Ruzza C, Argentieri M, Ferrari F, Armani E, Trevisani M, Marchini G, Calo' G.   +6 more
europepmc   +1 more source

Discovery of Chemical Scaffolds as Lysophosphatidic Acid Receptor 1 Antagonists: Virtual Screening, In Vitro Validation, and Molecular Dynamics Analysis. [PDF]

ACS Omega, 2023
Nguyen LP, Khan RA, Kang S, Lee H, Hwang JI, Kim HR.   +5 more
europepmc   +1 more source